Clinical Trials Logo

Filter by:
NCT ID: NCT05976360 Completed - Healthy Volunteer Clinical Trials

A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants

Start date: November 2, 2014
Phase: Phase 1
Study type: Interventional

This is a phase 1, single subcutaneous dose study to evaluate safety and pharmacokinetics of 2 different dupilumab drug product in healthy volunteers. The duration per participant is up to 11 weeks.

NCT ID: NCT05976282 Completed - Colorectal Cancer Clinical Trials

Addressing Colorectal Cancer in South Florida Firefighters

Start date: March 15, 2016
Phase: N/A
Study type: Interventional

The standard way of screening for colorectal cancer is to have a series of fecal blood tests, where a sample is taken from a participant's stool, or an endoscopic procedure performed by a doctor, where a camera is used to look inside the bowel. This research study will use a test performed by the participant. This test will look for changes in the stool that can identify if participants are at higher risk for cancer. Another aim of this study is to better understand what firefighters and retired firefighters think about colorectal cancer and other health issues. This information will help us develop programs that may improve colorectal cancer outcomes in the firefighter community.

NCT ID: NCT05976217 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis

Start date: October 1, 2023
Phase: Early Phase 1
Study type: Interventional

Based on preclinical data, investigators hypothesize that apoptosis resistance in monocyte-derived macrophages (MDMs) have a decisive role in the development of idiopathic pulmonary fibrosis (IPF). Specifically, macrophages from subjects with IPF have increased expression of Bcl-2 in mitochondria. In preclinical models of IPF, a conditional deletion of Bcl-2 in MDMs reverses established fibrosis by inducing apoptosis. Additional evidence to suggest that Bcl-2 expression in MDM mitochondria is a therapeutic target for IPF as administration of the Bcl-2 inhibitor, ABT-199 (Venetoclax), showed marked efficacy in preclinical models of IPF by inducing apoptosis of MDMs and reversing established fibrosis. ABT-199 is an orally available mimetic of the BH3 domain of Bcl-2, which is the domain the anchors Bcl-2 in the mitochondria to inhibit apoptosis. ABT-199 has shown therapeutic efficacy and good safety and tolerability in patients with chronic lymphocytic leukemia. Investigators anticipate that treatment with ABT-199 could result in significant benefit for IPF patients that have a life expectancy of 3-5 years. As there is no curative therapy for IPF, this clinical trial has the potential to substantially alter treatment approaches in patients with IPF.

NCT ID: NCT05975060 Completed - COVID-19 Clinical Trials

A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

COVID-19
Start date: September 7, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This is a Phase 2/3 open-label study to evaluate the safety and immunogenicity of a booster dose of the XBB.1.5 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccine (SARS-CoV-2 rS) adjuvanted with Matrix-M™ in previously mRNA COVID-19 vaccinated adult participants ≥18 years of age and baseline SARS CoV-2 seropositive COVID-19 vaccine naïve participants ≥18 years of age.

NCT ID: NCT05974865 Completed - Health Literacy Clinical Trials

Amelioration of Literacy Deficits in Prenatal Care

Start date: September 2006
Phase: N/A
Study type: Interventional

The purpose of the study was to develop and evaluate a skill-based, computer intervention designed to facilitate effective prenatal visit communication for women with restricted literacy.

NCT ID: NCT05974501 Completed - Postoperative Pain Clinical Trials

Pre vs Post Block in Total Knee Arthroplasty (TKA)

Start date: September 29, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this project is to determine if a change in patient reported pain, nausea and vomiting after total knee arthroplasty can be observed with the substitution of a post operative adductor canal block for a preoperative adductor canal block in the current established peri-operative pain protocol and if these changes lead to a decrease in opioid consumption (in morphine equivalents).

NCT ID: NCT05974046 Completed - Opioid Use Disorder Clinical Trials

Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants

Start date: July 10, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this open label study is to characterise the absorption, metabolism, excretion, and mass balance of [14C]-IDV184001AN ([14C]-IDV184001) in healthy adult male participants.

NCT ID: NCT05973747 Completed - Pregnancy Related Clinical Trials

Pharmacokinetic Equivalence of Calcium Gluconate and Calcium Chloride in Parturients

Start date: August 19, 2023
Phase: Early Phase 1
Study type: Interventional

Calcium is a life saving medicine in the care of parturients. It has many important uses including treatment of hypocalcemia, treatment of magnesium toxicity, prevention of hypocalcemia during blood transfusion (of citrate containing blood products), treatment of hyperkalemia, and others. Recent clinical trials also suggest that calcium given after cord clamping may decrease blood loss in patients undergoing cesarean delivery. 2 FDA approved forms of calcium can be given intravenously: calcium chloride and calcium gluconate. Over the last decade there have been times with drug shortages of either calcium chloride or calcium gluconate. So there have been and likely will continue to be times when one formulation or the other may not be adequately available. Despite the importance of calcium and the frequency in which it is used in parturients, there are no published studies in parturients to determine dose equivalence between calcium gluconate and calcium chloride. In this study the investigators will determine the population pharmacokinetics of calcium gluconate and calcium chloride in parturients and calculate the dose equivalent ratio the two drugs. This will help clinicians select appropriate doses of calcium and provide resilience to the drug supply chain in our era of frequent drug shortages.

NCT ID: NCT05973396 Completed - Muscle Weakness Clinical Trials

The Effects of Mental and Physical Fatigue to Force Production in Adults

Start date: July 18, 2022
Phase: N/A
Study type: Interventional

The primary objective is to investigate the correlation between physical and mental fatigue to lower extremity force production in adults to determine if there is an association of performance output that is inhibited by mental and physical stressors that mimic sport environments that can be further investigated to determine the importance of not only physical training and exercise for athletes, but also mental and cognitive exercises with physical task to enhance performance training and rehabilitation of individuals. In adults, how does physical and mental fatigue in combination compared to those who are just physically fatigued affect average peak height in performance of five CMJ with hands on hips.

NCT ID: NCT05972941 Completed - Clinical trials for Tobacco-Related Carcinoma

Nicotine and Tobacco Message Framing Among LGBT Young Adults

Start date: June 19, 2023
Phase: N/A
Study type: Interventional

This trial refines and evaluates how cultural targeting influences the effectiveness of anti-tobacco messages among lesbian, gay, bisexual, and transgender (LGBT) young adults at risk for the use of more than one tobacco product (polytobacco use). Polytobacco use is associated with nicotine dependence and tobacco use into adulthood, and is disproportionately high among LGBT young adults. This trial seeks to determine how cultural targeting can be applied to communicate polytobacco use risk to at-risk LGBT young adults.